COCP vs RDVT vs IDN vs AGEN vs MRK

For growth investors, Red Violet, Inc.

(RDVT) is the stronger pick with 20. 0% revenue growth year-over-year, versus -100. 0% for Intellicheck, Inc. (IDN). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate Red Violet, Inc. (RDVT) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus Red Violet, Inc. at 53. 9x. On forward P/E, Agenus Inc. is actually cheaper at 2. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Red Violet, Inc.

(RDVT) delivered a total return of +155. 9%, compared to -93. 9% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: IDN returned +301. 1% versus COCP's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Intellicheck, Inc.

(IDN) is the lower-risk stock at 0. 33β versus Agenus Inc. 's 2. 58β — meaning AGEN is approximately 691% more volatile than IDN relative to the S&P 500. On balance sheet safety, Red Violet, Inc. (RDVT) carries a lower debt/equity ratio of 3% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Red Violet, Inc.

(RDVT) is pulling ahead at 20. 0% versus -100. 0% for Intellicheck, Inc. (IDN). On earnings-per-share growth, the picture is similar: Intellicheck, Inc. grew EPS 100. 0% year-over-year, compared to 8. 0% for Merck & Co. , Inc.. Over a 3-year CAGR, RDVT leads at 19. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 0. 0% for Intellicheck, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -18. 0% for AGEN. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 2. 9x forward P/E versus 71. 4x for Intellicheck, Inc. — 68. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 95. 5% to $7. 33.

In this comparison, MRK (2.

9% yield), RDVT (0. 6% yield) pay a dividend. COCP, IDN, AGEN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 2. 9% yield, +164. 7% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRK: +164. 7%, AGEN: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (COCP (Healthcare) and RDVT (Technology) and IDN (Technology) and AGEN (Healthcare) and MRK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: COCP is a small-cap quality compounder stock; RDVT is a small-cap high-growth stock; IDN is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; MRK is a large-cap deep-value stock. RDVT, MRK pay a dividend while COCP, IDN, AGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.